
Synthesis and Characterization of New Conjugated Systems Derived
from
Piperazine-2,5-dione with antimicrobial
screening

*Muna.I.Khalaf***, *Mayson.T.Tawffeaq**
*,Ahlam.j.zayer**

** College of Science / University of Baghdad / Iraq
(corresponding)

* College of Education For Pure Science (Ibn Al-Haitham) / University of Baghdad
/ Iraq

Abstract:

The preparation of monoarylidene and unsymmetrical bisarylidene derivatives of 2,5- Piperazine dione is described. The use of 1,4-diacetylpiperazine 2,5-dione make it possible to prepare unsymmetrical bisarylidenes.

Antibacterial activity of the prepared new compounds against five types of bacteria were evaluated and the results showed that the new compounds exhibit good to moderate antibacterial activity.

Keywords: Piperazine-2,5-dione, arylidene, bisarylidene, cyclic dipeptides, unsymmetrical

تحضير وتشخيص أنظمة متبادلة جديدة مشتقة من جزئي ٢, ٥- ببرازين دايون واختبار الفعالية الميكروبية لها

منى اسماعيل خلف# وميسون طارق توفيق### واحلام جاسم زاير###

#قسم الكيمياء اكلية العلوم اجامعة بغداد

قسم الكيمياء اكلية التربية الاساسية ابن الهيثم اجامعة بغداد

الخلاصة:

تم في هذا البحث الحصول على مشتقات جديدة من جزيئة 2, ٥- ببرازين دايون احادية التعويض وغير متناظرة عن طريق استئلته ثم مفاعلتها مع الفورفورال اولا للحصول على المشتق الاحادي التعويض. بعدها مفاعلة المشتق الاحادي التعويض مع الديهايدات اروماتية مختلفة للحصول على نظام حلقي متبادل. تم اختبار الفعالية الميكروبية للمركبات المحضرة مع خمس انواع من البكتريا وقد اظهر الاختبار نتائج اولية جيدة .

الكلمات المفتاحية:- ٢, ٥ – ببرازين دايون ، الفورفورال ، نظام حلقي متبادل ،متناظر وغير متناظر

Introduction:

piperazines and their derivatives have been known for more than a century, only recently have 2,5-diketopiperazines attracted attention due to their biological properties. The piperazine-2,5-dione moiety occurs in a variety of drugs and natural products which span a wide spectrum of biological activities, *e.g.*, roquefortine, [1,2] bicyclomycin [3] dipodazine [4] neihumicin [5] phomamide [6] and dihydrodysamide C [7]. Additionally, this heterocyclic system has found unique applications as an acceptor for organic anions or metal cations [8] and in material sciences [9]. The chemistry of piperazine-2,5-dione attracts great interest. Recent studies showed that 3-salicylidene piperazine-2,5-dione was supposed to be the most promising precursor for the synthesis of spiro[benzofuran-2(3H)-2'-piperazine]-

3',6'-dione as a main skeleton of aspirochlorine [10-11]. 2,5-diketopiperazines (DKPs, also known as cyclic dipeptides, 2,5-dioxopiperazines, cyclo(dipeptides), or anhydride dipeptides) are the smallest cyclopeptides. These peptides are most commonly found as natural products [12], showing antimicrobial [13], antitumoral and antiviral [14], cytotoxic [15], and neuroprotective effects [16], among other activities. Some DKPs are stable to proteolysis (enzymatic degradation), an important feature for their high activity. All these properties make DKPs an interesting group of molecules for the development of new therapeutic agents. This paper deals with the synthesis of mono- and bisarylidene (unsymmetric) derivative

Experimental

Products were characterized by UV spectrophotometer (Table 1), $^1\text{H-NMR}$ Spectra (Table 2) and IR spectra (Tables 3). The melting points were determined on a Kofler Block apparatus and are uncorrected. Infrared spectra were recorded in 400 - 4000 cm^{-1} region by a Specord FT-IR Jusco 300 spectrometer using KBr disk. $^1\text{H-NMR}$ Spectra were measured on ambient Bruker DT-400 MHz spectrometer in deuterated CDCl_3 , and UV-visible were determined with Shimadzu 190A spectrometer. CHN analysis were determined on Elementer-vario Micro-CUBE. The magnetic stirrer and the other necessary laboratory equipment used. All fine chemicals and reagents were purchased from Aldrich chemical Co. U.S.A. and microbial activity were done in the biology department laboratories.

Synthesis of compound (II): 1, 4-Diacetylpiperazine-2, 5-Dione:

1,4-Diacetylpiperazine-2,5-dione (II) was prepared by treating compound (I) with Acetic anhydride under reflux for 6 hr. [17].

Synthesis of: III:

A mixture of 1,4-diacetylpiperazine-2,5-dione(**II**) (0.001 mole), furylaldehyde(**I**) (0.001 mole) and triethylamine (0.001 mole) ,in 5 ml DMF was stirred at room temperature for 12 hrs.(Table 1) The resulting yellow precipitate was filtered off and washed with water. Recrystallization from ethanol gave the pure monosubstituted derivative **III**. (Yield 75%),[18].

Synthesis of: IV, V, VI:

General procedure for the preparation of unsymmetrical bisarylidenes:

A solution of 1-acetyl-3-(3-furylmethylidene) piperazine-2, 5-dione **III** (0.01 moles), an aldehyde(Salicylaldehyde ,anisaldehyde ,2,4-dihydroxybenzaldehyde) (0.01 moles) and triethylamine (0.01 moles) in DMF (25 ml) was stirred at 25°C for 24 hrs. The precipitate was filtered off and washed with water and a small amount of cooled ethanol (10 ml). The pure samples were obtained after recrystallization from dimethyl formamide (see Tables 1 & 2).

Table 1.physical properties, CHN analysis

Found%	Calculated%	λ_{max}, nm	Time, (hr.)	Yield %	M.P C ⁰	Mr. Formula	Comp.
C H N	C H N						
56.42,4.23,11.50	56.41; 4.30; 11.96	335	12	78	178-179	C ₁₁ H ₁₀ N ₂ O ₄ 234.35	III
64.45, 4.16,9.35	64.86; 4.08; 9.46	411	24	68	279-280	C ₁₆ H ₁₂ N ₂ O ₄ 296.36	IV
66.02,4.35,8.98	65.80; 4.55; 9.03	428	24	72	284-285	C ₁₇ H ₁₄ N ₂ O ₄ 310.39	V
61,90,3.62,9.03	61.54; 3.87; 8.97	445	24	75	191-193	C ₁₆ H ₂₁ N ₂ O ₅ 312.36	VI

Results and Discussion:

A four Knoevenagel products (III, IV, V, VI) were obtained by condensation of active methylene heterocyclic compound Piperazine 2,5-dione with (some aryl aldehydes) in the chosen solvent, in normal conditions. All condensation products are stable solid compounds, rather insoluble in common solvents, with high melting points. (Table 1).

¹H-NMR spectra of the compounds (IV, V, VI), indicate disappearance of proton signals for the (methylene, and aldehyde groups) of the compounds (IV, V, VI) at δ (4, 10) ppm, and appearance of a protons of olefins (H- α - protons) and (aromatic ring) at (6.4-8.6) ppm for all prepared compounds. Also ¹H-NMR spectral analysis shows proton signals of NH group at δ (10.76, 10.61) ppm for all compounds except III at 9.1 ppm, where compound III appears to save a signal at δ (4.316) ppm belongs to methylene group as expected to be mono substituted product. While disappearance of this signal in spectra of the IV, V, VI compounds (indicate unsymmetrical di substituted) are shown in (Table 2).

The resonance signals and their multiplicity confirmed the proposed structures, while study of this data (H-NMR) enable us to expect the configuration stereo structure (Z-S-Trans of compound III and (Z, Z-S, S⁻-Trans) of IV, V, VI, compounds fig.7,8.[18]

Table 2. ¹H NMR spectra data of prepared compounds. III-VI

¹ H NMR spectra (ppm)	SOLVENT	COMPS.
δ ; 1.7 (S, 3H, COCH ₃); 4.50 (S, 2H, CH ₂); 6.65-7.83 (m, 3H-Furan); 7.82 (S, 1H, =CH) , 9.12 (S, 1H, NH)	CDCl ₃	III
δ ; 6.54-7.87 (m, 7H, Ar, Furan); 6.46 (S, 1H, =CH); 6.7 (S, 1H, =CH); 10.76 (S, 2H, NH).	CDCl ₃	IV
δ ; 1.45 (S, 3H, CH ₃ O) 6.51-7.82 (m, 7H, Ar, Furan); 6.53, 6.7 (S, 2H, =CH); 10.61 (S, 2H, NH).	CDCl ₃	V
δ ; 6.14-7.81 (m, 7H, Ar, Furan); 6.56 (S, 1H, =CH); 6.79 (S, 1H, =CH); 10.76 (S, 2H, NH).	CDCl ₃	IV

Where the infrared spectra of the prepared compounds III, IV, V, VI showed strong absorption bands of the C=C and C=O stretching vibrations in two very well distinguished regions 1620 - 1624 cm⁻¹ and 1698 - 1733 cm⁻¹ (Table 2). The absorption bands in the lower

region of the spectra (1400-1600) cm^{-1} belong to the (C=C) of the furan ring and aromatic ring. The higher region of spectrum was attributed to the heterocyclic part (-NH) of the compounds. (Table 3) .UV spectra showed red-shift phenomena for all prepared compounds attributed to furan ring as conjugation bridge with formed C=C bond [19] (table-1).

Table 3. IR spectral data of synthesized compounds III-VI

other	ν (cm-1)				Comps.
	ν C=C olefenc	ν C=C Ar, furan	ν C=O heterocyclic	ν NH	
	1625	1463,1492,1575	1700	3218	III
3380- OH	1627	1448,1480,1571	1686	3278	IV
2991,2944 CH ₃ aliphatic	1631	1417-1487,1558	1694	3276	V
4030- OH	1639	1434,1467,1585	1683	3255	VI

Table 4: Antimicrobial screening results of the tested compounds at (50,100) μg /ml concentration.

<i>Pseudomons</i> (sp)	<i>S.aureus</i>	<i>K.Pneumonia</i>	<i>Strep.</i> <i>pneumonia</i>	<i>E.coli</i>	Conc.	No
++	+++	++	-	-	50 μg	III
+++	++	++	-	-	100 μg	
++	++	+	-	-	50 μg	IV
+++	++	++	-	++	100 μg	
++	++	+	++	+	50 μg	V
+++	++	++	-	-	100 μg	
++	-	+	-	+	50 μg	VI
+++	++	+	-	++	100 μg	




Fig .1. I.R spectrum of III




Fig. 2 . IR spectrum of IV




Fig. 3 . IR spectrum of V




Fig. 4 . IR spectrum of VI




Fig.9. Expected stereo configuration to compound III at lowest level energy as obtained from MM2 program




Fig.10. Expected stereo configuration to compound IV-VI at lowest level energy as obtained from MM2 program

Referances

1. Chen, W. C.; Joullie, M. M. *Tetrahedron Lett.* **1998**, *39*, 8401-8404.
2. Ohmomo, S.; Oguma, K.; Ohashi, T.; Abe, M. *Agric. Biol. Chem.* **1978**, *42*, 2387-2389.
3. Bradley, E. L.; Herbert, R. B.; Lawrie, K. W. M.; Khan, J. A.; Moody, C. M.; Young, D. W. *Tetrahedron Lett.* **1996**, *37*, 6935-6938.
4. Sorensen, D.; Larsen, T. O.; Christophersen, C.; Nielsen, P. H.; Anthoni, U. *Phytochem.* **1999**, *51*, 1181-1183.
5. Yokoi, T.; Yang, L. M.; Yokoi, T.; Wu, R. Y.; Lee, K. H. *J. Antibiot.* **1988**, *41*, 494-501.
6. Ferezou, J. P.; Quesneau-Thierry, A.; Barbier, M.; Kollmann, A.; Bousquet, J. F. *J. Chem. Soc., Perkin Trans. 1* **1980**, 113-115.
7. Dumdei, E. J.; Simpson, J. S.; Garson, M. J.; Byriell, K. A.; Kennard, C. H. L. *Australian J. Chem.* **1997**, *50*, 139-144
8. Fuji, K.; Takasu, K.; Miyamoto, H.; Tanaka, K.; Taga, T. *Tetrahedron Lett.* **1996**, *37*, 7111-7114.
9. Li, W.-R.; Kao, K.-C.; Yo, Y.-C.; Lai, C. K. *Helv. Chim. Acta.* **1999**, *82*, 1400-1407.
10. Shin, C.; Nakajima, Y.; Sato, Y. *Chem. Lett.* **1984**, 1301.
11. Sakata, K.; Massgo, H.; Sakurai, A.; Takahashi, N. *Tetrahedron Lett.* **1982**, *23*, 2
12. Prasad, C. Bioctive cyclic dipeptides. *Peptides* **1995**, *16*, 151-164.
13. Houston, D.R.; Synstad, B.; Eijsink, V.G.H.; Stark, M.J.R.; Eggleston, I.M.; van Aalten, D.M.F. Structure-based exploration of cyclic dipeptide chitinase inhibitors. *J. Med. Chem.* **2004**, *47*, 5713-5720.
14. Martins, M.B.; Carvalho, I. Diketopiperazines: biological activity and synthesis. *Tetrahedron*

2007, 63, 9923-9932.

15. Graz, C.J.M.; Grant, G.D.; Brauns, S.C.; Hunt, A.; Jamie, H.; Milne, P.J. Cyclic dipeptides in the induction of maturation for cancer therapy. *J. Pharm. Pharmacol.* **2000**, 52, 75-82.

16. Prakash, K.R.C.; Tang, Y.; Kozikowski, A.P.; Flippen-Anderson, J.L.; Knobloch, S.M.; Faden, A.I. Synthesis and biological activity of novel neuroprotective diketopiperazines. *Bioorg. Med. Chem.* **2002**, 10, 3043-3048.

17-Marcuccio, S. M.; Elix, J. A. *Aust. J. Chem.* **1984**, 37, 1791.

18- "Study of condensation reaction of furfural derivatives with heterocyclic compounds containing active hydrogen atoms" ,Muna.I.Khalaf, Abdo .Aand Farouk .K,thesis of Ph.D,2012

19-Wei ZHANG,Jian LI HUA,Jian Gui QIN,"synthesis and nonlinear optical property Of a series of new chromophor furan ring as the only conjugation bridge",Chinese chemical letters (2002),13,10,p945-948.